Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8140621 | 0.84 | TNFRSF1A (0.64) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8140626 | 0.84 | TNFRSF1A (0.64) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5427616 | 0.80 | NFE2L2 (0.64) | MAPTKDM4EALDH1A1MAOBLMNA | |
| SCHEMBL29935293 | 0.80 | MAPT (0.67) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1285839 | 0.80 | MAPT (0.67) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1285840 | 0.80 | MAPT (0.67) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3118705 | 0.79 | SMN1; SMN2 (0.52) | TNFRSF1AMAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL8686533 | 0.79 | MAPT (0.65) | TNFRSF1AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30307308 | 0.77 | TNFRSF1A (0.78) | TNFRSF1AMAPTALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL16211002 | 0.77 | TNFRSF1A (0.78) | TNFRSF1AMAPTALDH1A1SMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | claimed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | claimed |
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | disclosed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| CN-101111475-B | Antiviral compounds and methods | BIOTRON LTD | 2012-09-05 | — | — | CN | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | TNFRSF1A 3672/4885MAPT 3427/4885KDM4E 1864/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | TNFRSF1A 3672/4885MAPT 3427/4885KDM4E 1864/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | TNFRSF1A 3646/4885MAPT 3545/4885KDM4E 1719/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | TNFRSF1A 3672/4885MAPT 3427/4885KDM4E 1864/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | TNFRSF1A 3643/4885MAPT 3702/4885KDM4E 1804/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | TNFRSF1A 3643/4885MAPT 3702/4885KDM4E 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.